YU98902A - Derivati aza premošćenih bicikličnih amino kiselina kao antagonisti alfa4 integrina - Google Patents
Derivati aza premošćenih bicikličnih amino kiselina kao antagonisti alfa4 integrinaInfo
- Publication number
- YU98902A YU98902A YU98902A YUP98902A YU98902A YU 98902 A YU98902 A YU 98902A YU 98902 A YU98902 A YU 98902A YU P98902 A YUP98902 A YU P98902A YU 98902 A YU98902 A YU 98902A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- aza
- amino acid
- compounds
- acid derivatives
- integrin antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Ovaj pronalazak se odnosi na aza-premošćena biciklična jedinjenja koja imaju formulu (I) i njene farmaceutski prihvatljive soli. Jedinjenja su korisna kao antagonisti α4 receptora integrina, a naročito kao antagonisti α4β1 i α4β7 receptora integrina. Pronalazak se dalje odnosi na postupak za upotrebu ovih jedinjenja za lečenje poremećaja u kojima posreduje integrin uključujući, ali se ne ograničavajući samo na, zapaljenja, poremećaje autoimuniteta i poremećaje ćelijske proliferacije, postupke za pripremanje jedinjenja i postupke za pripremanje intermedijera, derivata i njihovih farmaceutskih kompozicija.[The invention is directed to aza-bridged-bicyclic compounds having Formula (I): Formula (I) and pharmaceutically acceptable salts thereof. The compounds are useful α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21569500P | 2000-06-30 | 2000-06-30 | |
US09/891,602 US6960597B2 (en) | 2000-06-30 | 2001-06-26 | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
YU98902A true YU98902A (sh) | 2006-05-25 |
Family
ID=26910288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU98902A YU98902A (sh) | 2000-06-30 | 2001-06-29 | Derivati aza premošćenih bicikličnih amino kiselina kao antagonisti alfa4 integrina |
Country Status (19)
Country | Link |
---|---|
US (1) | US6960597B2 (sh) |
EP (1) | EP1303492A2 (sh) |
JP (1) | JP2004506612A (sh) |
KR (1) | KR20030014287A (sh) |
CN (1) | CN1449385A (sh) |
AR (1) | AR031853A1 (sh) |
AU (1) | AU2001273095A1 (sh) |
BR (1) | BR0112359A (sh) |
CA (1) | CA2415088A1 (sh) |
HK (1) | HK1052343A1 (sh) |
HU (1) | HUP0301195A2 (sh) |
IL (1) | IL154053A0 (sh) |
MX (1) | MXPA03000814A (sh) |
NO (1) | NO20026252L (sh) |
NZ (1) | NZ523852A (sh) |
PL (1) | PL359997A1 (sh) |
RU (1) | RU2003102631A (sh) |
WO (1) | WO2002002556A2 (sh) |
YU (1) | YU98902A (sh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
SK287781B6 (sk) | 2000-08-18 | 2011-09-05 | Ajinomoto Co., Inc. | Fenylalanínové deriváty, farmaceutický prípravok s ich obsahom a ich použitie |
EP1323711B1 (en) | 2000-09-29 | 2006-11-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
US7115628B2 (en) * | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
WO2004066931A2 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
CN103784458B (zh) | 2003-12-22 | 2015-10-14 | 味之素株式会社 | 苯基丙氨酸衍生物 |
CN1938283A (zh) * | 2004-02-10 | 2007-03-28 | 詹森药业有限公司 | 作为α4整联蛋白拮抗剂的哒嗪酮 |
AR047537A1 (es) * | 2004-02-10 | 2006-01-25 | Janssen Pharmaceutica Nv | Piridazinonaureas como antagonistas de integrinas |
US7220742B2 (en) * | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
AR049200A1 (es) | 2004-06-04 | 2006-07-05 | Genentech Inc | Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20 |
US20060223846A1 (en) * | 2005-03-08 | 2006-10-05 | Dyatkin Alexey B | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
CA2617546C (en) | 2005-08-03 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
BRPI0614410A2 (pt) * | 2005-08-15 | 2011-03-29 | Boehringer Ingelheim Int | processo para preparação de betamiméticos |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JP2013513664A (ja) * | 2009-12-14 | 2013-04-22 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 架橋二環式rhoキナーゼ阻害化合物、組成および使用 |
WO2011094890A1 (en) * | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
US8999975B2 (en) * | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
TW201334789A (zh) | 2012-01-31 | 2013-09-01 | Genentech Inc | 抗ige抗體及其使用方法 |
DK2970283T3 (da) | 2013-03-14 | 2021-01-25 | Boehringer Ingelheim Int | Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c |
WO2014140091A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
CA2913791A1 (en) * | 2013-06-11 | 2014-12-18 | Receptos, Inc. | Novel glp-1 receptor modulators |
WO2016016242A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
SI3191487T1 (sl) | 2014-09-12 | 2019-12-31 | Boehringer Ingelheim International Gmbh | Spirociklični inhibitorji katepsina C |
KR20240107346A (ko) | 2015-10-06 | 2024-07-09 | 제넨테크, 인크. | 다발성 경화증을 치료하기 위한 방법 |
DK3538542T3 (da) | 2016-11-11 | 2021-10-11 | Zealand Pharma As | Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin |
WO2020092401A1 (en) * | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
CA3116769C (en) | 2018-10-30 | 2023-08-22 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリンの阻害のための化合物 |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
EP4013499A1 (en) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905971A (en) | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
JPS6314774A (ja) | 1986-07-07 | 1988-01-21 | Mitsubishi Chem Ind Ltd | ピリダジノン誘導体又はその塩類 |
IE62890B1 (en) | 1988-12-06 | 1995-03-08 | Hafslund Nycomed Pharma | New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure |
US6090785A (en) | 1992-10-15 | 2000-07-18 | Merck & Co., Inc. | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents |
US5525623A (en) | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
US5827866A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
US5827860A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
US5523308A (en) | 1995-06-07 | 1996-06-04 | Costanzo; Michael J. | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
ATE318841T1 (de) | 1997-05-29 | 2006-03-15 | Merck & Co Inc | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
US6291511B1 (en) | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
CA2291778A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
US6221888B1 (en) | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
JP2001512138A (ja) | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Vla−4が介在する白血球付着を阻害するベンジル化合物 |
JP2001512137A (ja) | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Vla−4により媒介される白血球の付着を阻害するジペプチド化合物 |
CA2290746A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
AU742928C (en) | 1997-08-22 | 2003-02-20 | F. Hoffmann-La Roche Ag | N-alkanoylphenylalanine derivatives |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
NZ502813A (en) | 1997-08-22 | 2002-10-25 | F | N-aroylphenylalanine derivatives as inhibitors of the interaction between a4 containing integrins and VCAM-1 |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
NZ503407A (en) | 1997-10-31 | 2002-08-28 | Aventis Pharma Ltd | Anilide derivatives useful for treating inflammatory diseases |
US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
ATE273273T1 (de) | 1998-02-26 | 2004-08-15 | Celltech Therapeutics Ltd | Phenylalaninderivate als inhibitoren von alpha4 integrinen |
US6121280A (en) | 1998-03-24 | 2000-09-19 | Pfizer Inc. | Azabicyclic rotomase inhibitors |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821406D0 (en) | 1998-10-01 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
WO2000043354A2 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
EP1147097A1 (en) | 1999-01-27 | 2001-10-24 | Ortho-Mcneil Pharmaceutical, Inc. | Peptidyl heterocyclic ketones useful as tryptase inhibitors |
BR0008280A (pt) | 1999-02-18 | 2001-11-06 | Hoffmann La Roche | Derivados de tioamida |
ATE264298T1 (de) | 1999-03-01 | 2004-04-15 | Elan Pharm Inc | Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten |
WO2001012183A1 (en) | 1999-08-16 | 2001-02-22 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
AU6909300A (en) | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
US20030130166A1 (en) | 1999-08-24 | 2003-07-10 | Sonia Cunningham | Polynucleotide encoding a human junctional adhesion protein (JAM2) |
ATE364592T1 (de) | 1999-09-24 | 2007-07-15 | Genentech Inc | Tyrosinderivate |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
DE19950862C5 (de) | 1999-10-21 | 2004-02-26 | Lucas Varity Gmbh | Betätigungseinheit für eine elektronisch gesteuerte Fahrzeugbremsanlage |
AU7961200A (en) | 1999-10-29 | 2001-05-14 | Kaken Pharmaceutical Co., Ltd. | Urea derivative, process for producing the same, and medicine containing the urea derivative |
ATE355269T1 (de) | 1999-11-18 | 2006-03-15 | Ajinomoto Kk | Phenylalaninderivate |
CN1218943C (zh) | 1999-12-06 | 2005-09-14 | 霍夫曼-拉罗奇有限公司 | 4-嘧啶基-n-酰基-l-苯基丙氨酸类化合物 |
US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
WO2001042215A1 (en) | 1999-12-06 | 2001-06-14 | F. Hoffmann-La Roche Ag | 4-pyridinyl-n-acyl-l-phenylalanines |
US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
NZ519447A (en) | 1999-12-16 | 2004-03-26 | Biogen Inc | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
BR0016818A (pt) | 1999-12-28 | 2002-10-01 | Pfizer Prod Inc | Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias |
AU2001233069A1 (en) | 2000-01-28 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
US6403584B1 (en) | 2000-06-22 | 2002-06-11 | Merck & Co., Inc. | Substituted nipecotyl derivatives as inhibitors of cell adhesion |
US6579889B2 (en) | 2000-06-22 | 2003-06-17 | Merck & Co., Inc. | Substituted isonipecotyl derivatives as inhibitors of cell adhesion |
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
WO2002008202A2 (en) | 2000-07-21 | 2002-01-31 | Elan Pharmaceuticals, Inc. | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4 |
US7015216B2 (en) * | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
SK287781B6 (sk) | 2000-08-18 | 2011-09-05 | Ajinomoto Co., Inc. | Fenylalanínové deriváty, farmaceutický prípravok s ich obsahom a ich použitie |
US6709192B2 (en) | 2000-09-05 | 2004-03-23 | The Fort Miller Group, Inc. | Method of forming, installing and a system for attaching a pre-fabricated pavement slab to a subbase and the pre-fabricated pavement slab so formed |
AU2001286242A1 (en) | 2000-09-14 | 2002-03-26 | Toray Industries, Inc | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient |
GB0028844D0 (en) | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
US6559174B2 (en) | 2001-03-20 | 2003-05-06 | Merck & Co., Inc. | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors |
JP4164871B2 (ja) | 2001-07-26 | 2008-10-15 | 味の素株式会社 | 新規フェニルプロピオン酸誘導体 |
-
2001
- 2001-06-26 US US09/891,602 patent/US6960597B2/en not_active Expired - Fee Related
- 2001-06-29 CA CA002415088A patent/CA2415088A1/en not_active Abandoned
- 2001-06-29 AU AU2001273095A patent/AU2001273095A1/en not_active Abandoned
- 2001-06-29 KR KR1020027017914A patent/KR20030014287A/ko not_active Application Discontinuation
- 2001-06-29 PL PL01359997A patent/PL359997A1/xx not_active Application Discontinuation
- 2001-06-29 AR ARP010103131A patent/AR031853A1/es unknown
- 2001-06-29 IL IL15405301A patent/IL154053A0/xx unknown
- 2001-06-29 EP EP01952331A patent/EP1303492A2/en not_active Withdrawn
- 2001-06-29 NZ NZ523852A patent/NZ523852A/en unknown
- 2001-06-29 CN CN01814699A patent/CN1449385A/zh active Pending
- 2001-06-29 RU RU2003102631/04A patent/RU2003102631A/ru not_active Application Discontinuation
- 2001-06-29 YU YU98902A patent/YU98902A/sh unknown
- 2001-06-29 WO PCT/US2001/020857 patent/WO2002002556A2/en active IP Right Grant
- 2001-06-29 MX MXPA03000814A patent/MXPA03000814A/es unknown
- 2001-06-29 BR BR0112359-9A patent/BR0112359A/pt not_active IP Right Cessation
- 2001-06-29 HU HU0301195A patent/HUP0301195A2/hu unknown
- 2001-06-29 JP JP2002507808A patent/JP2004506612A/ja active Pending
-
2002
- 2002-12-27 NO NO20026252A patent/NO20026252L/no not_active Application Discontinuation
-
2003
- 2003-06-19 HK HK03104413.8A patent/HK1052343A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PL359997A1 (en) | 2004-09-06 |
HK1052343A1 (zh) | 2004-02-06 |
US20020091115A1 (en) | 2002-07-11 |
AR031853A1 (es) | 2003-10-08 |
RU2003102631A (ru) | 2004-09-27 |
JP2004506612A (ja) | 2004-03-04 |
HUP0301195A2 (hu) | 2003-08-28 |
IL154053A0 (en) | 2003-07-31 |
NO20026252L (no) | 2003-02-26 |
CN1449385A (zh) | 2003-10-15 |
US6960597B2 (en) | 2005-11-01 |
MXPA03000814A (es) | 2004-11-01 |
CA2415088A1 (en) | 2002-01-10 |
WO2002002556A3 (en) | 2002-07-18 |
EP1303492A2 (en) | 2003-04-23 |
BR0112359A (pt) | 2003-05-27 |
KR20030014287A (ko) | 2003-02-15 |
AU2001273095A1 (en) | 2002-01-14 |
NZ523852A (en) | 2004-11-26 |
WO2002002556A2 (en) | 2002-01-10 |
NO20026252D0 (no) | 2002-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU98902A (sh) | Derivati aza premošćenih bicikličnih amino kiselina kao antagonisti alfa4 integrina | |
WO2006038006A3 (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders | |
IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
WO2001023357A3 (en) | Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
TR200102489T2 (tr) | 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması | |
TW430663B (en) | Novel substituted piperidines useful for the treatment of allergic diseases | |
WO2001066534A3 (en) | Cyclic and bicyclic diamino histamine-3 receptor antagonists | |
MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
TW200531694A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
PT894084E (pt) | Derivados de acido cinamico e sua utilizacao como antagonistas de integrina | |
ATE187963T1 (de) | Neue 4-piperidinyl substituierte lactame als neukokinin 2 rezeptor antagonisten zur behandlung von asthma | |
IL174678A0 (en) | Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist | |
WO2006052962A3 (en) | Bicyclic triazole a4 integrin inhibitors | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
DE69838662D1 (de) | Morphinanderivate und ihre medizinische Anwendung | |
HUP0301272A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
YU30902A (sh) | Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju | |
GR3036639T3 (en) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist | |
BRPI0416102A (pt) | derivados de aminoácido bicìclico ligado a aza melhorados como antagonistas de integrina alfa4 | |
DK0882038T3 (da) | Substituerede N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamider til behandling af allergisygdomme | |
UA74421C2 (uk) | Похідні індолону, які є антагоністами gal3 рецептора для лікування депресії і/або тривоги та композиції, придатні для такого лікування | |
EP1172106A3 (en) | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists |